Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.
To determine the highest and safest tolerated dose of MDX-1411 for the treatment of clear cell renal cell carcinoma (Kidney cancer).
Kidney Cancer
BIOLOGICAL: MDX 1411
Determine the safety profile of MDX 1411, duration of study|Determine the maximum tolerated dose of MDX 1411, duration of study
Determine the best overall response rate (BORR), Day 38-42 of each cycle
Subjects will be assigned one dose upon enrollment and will continue with the same dose throughout the study. The maximum duration for the study is two and a half years for a total of 17 cycles.